Business
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-negative breast cancer. Caris GPSai®, the com
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-negative breast cancer. Caris GPSai®, the company's clinically validated tissue-of-origin AI model, available when ordering Caris MI Cancer Seek®, subsequently identified the true source of her disease as Hodgkin lymphoma, one of the most treatable cancers.","length":774,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DYkfDi5YhqiUCC4hCHfZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMw--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/xS87Ss8EcVJzBN8xSSK9jA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU3NA--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Erika presented in a visceral crisis and started chemotherapy based on an initial diagnosis of triple-negative breast cancer. Her treating oncologist, Vitor H. Pastorini Filho, MD, a board-certified hematologist and medical oncologist, questioned whether the clinical picture fit and ordered comprehensive molecular profiling with Caris GPSai to confirm th...